Comparative Pharmacology
Head-to-head clinical analysis: EULEXIN versus FLUTAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EULEXIN versus FLUTAMIDE.
EULEXIN vs FLUTAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone to androgen receptors in target tissues, thereby blocking androgen action.
Nonsteroidal antiandrogen; competitively inhibits androgen binding to androgen receptors, thereby blocking androgen action in target tissues.
250 mg orally three times daily (every 8 hours).
250 mg orally every 8 hours. Total daily dose: 750 mg.
None Documented
None Documented
5-6 hours for flutamide; 8-10 hours for active metabolite 2-hydroxyflutamide; requires three times daily dosing
Clinical Note
moderateFlutamide + Digoxin
"Flutamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateFlutamide + Digitoxin
"Flutamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateFlutamide + Deslanoside
"Flutamide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateFlutamide + Acetyldigitoxin
"Flutamide may decrease the cardiotoxic activities of Acetyldigitoxin."
Flutamide has an initial half-life of about 5–6 hours; its active metabolite, 2-hydroxyflutamide, has a terminal elimination half-life of 8–10 hours, supporting twice-daily dosing for steady-state concentrations.
Renal: 28% (as unchanged drug and metabolites, mainly 2-hydroxyflutamide), Biliary/Fecal: 4.2% (as metabolites)
Primarily renal (approximately 98% of absorbed dose as metabolites, with ~4.5% as the active metabolite 2-hydroxyflutamide); less than 1% excreted unchanged; biliary/fecal elimination is minimal (<1%).
Category C
Category D/X
Antiandrogen
Antiandrogen